U.S. mRNA Therapeutics Market Revenue to Attain USD 11.11 Bn by 2033

30 Dec 2024

Share :

Table of Content

1. U.S. mRNA Therapeutics Market Revenue and Trends 2023 to 2033 2. Market Overview 3. Report Highlights of the U.S. mRNA Therapeutics Market 4. U.S. mRNA Therapeutics Market Coverage 5. Major Trends in the U.S. mRNA Therapeutics Market 6. Country Insights 7. Market News 8. US mRNA Therapeutics Market Key Players

U.S. mRNA Therapeutics Market Revenue and Trends 2023 to 2033

The U.S. mRNA therapeutics market revenue was valued at USD 5.13 billion in 2024 and is expected to attain around USD 11.11 billion by 2033, growing at a notable CAGR of 9.00% during the forecast period. The rising number of clinical trials, high demand for ribonucleic acid-based vaccines and therapeutics, and the increasing use of stem cell therapies drive the market for U.S. mRNA therapeutics.

Market Overview

mRNA therapeutics use in vitro transcribed RNA to direct the translation of proteins with pharmacological activity in vivo. It carries the message of any gene and produces almost any functional protein or peptide for vaccination or protein replacement therapy. mRNA is used heavily in the production and commercialization of mRNA-based therapeutics that instruct cells in the body to produce specific proteins designed to encode for particular proteins with therapeutic benefits.

The mRNA platform helps with the rapid development of therapeutics and has a significant role in responding to infectious diseases or evolving medical needs. With the increasing number of infectious diseases, the demand for mRNA therapeutics is rising worldwide. Moreover, the rising demand for personalized medicines drives the U.S. mRNA therapeutics market.

Rising investments by public and private sectors and collaborations between pharmaceutical and biotechnology companies to accelerate the development of mRNA-based therapies positively impact the market. Integrating advanced technologies like artificial intelligence that accelerates the mRNA vaccine antigen design and conducts clinical trials, helping researchers to go from a viral sequence to an approved product in less time. Using machine learning and deep learning algorithms can accelerate the development of mRNA therapeutics than traditional methods, thus boosting the market.

Report Highlights of the U.S. mRNA Therapeutics Market

• By type, the prophylactic vaccines segment dominated the market with the largest share in 2024 due to the increased usage of these vaccines in treating infectious diseases. mRNA facilitates rapid vaccine development and produces vaccines in a shorter time than traditional methods. Moreover, heavy investments done by pharmaceutical companies and biotech firms in the development of mRNA-based vaccines bolstered the segment.
• By application, the oncology segment led the market in 2024. By tailoring mRNA sequences to specific tumor mutations or antigens, mRNA enables the development of personalized cancer therapies. The increased prevalence of cancer worldwide further augmented the segment.
• By end-user, the hospitals & clinics segment accounted for the largest market share in 2024 due to their significant role in administering mRNA vaccines that prevent the spread of the virus. Also, the rising number of clinical trials and regulatory approvals allows healthcare providers to integrate them into treatment protocols for treating diseases.

U.S. mRNA Therapeutics Market Coverage

Major Trends in the U.S. mRNA Therapeutics Market

• Development in mRNA-based Therapies: Developments in mRNA therapeutics are basically due to the advances in genomics and gene editing technologies. Moreover, rising developments in synthetic biology and bioinformatics contribute to the growth of the market.
• Rising Demand for Personalized Medicines: mRNA technologies can be tailored to target specific disease variants or genetic profiles and provide personalized medicine care with improved patient outcomes. mRNA vaccines and therapies are in high demand due to their effectiveness and safety profiles.
• Rising Prevalence of Chronic Diseases: Cases of chronic diseases are increasing rapidly due to the changing lifestyles and excessive consumption of tobacco and alcohol, which create a burden on the healthcare system and significantly boost the need for more effective treatment plans. However, mRNA-based therapeutics instruct cells to produce proteins offering targeted therapies and vaccines tailored to an individual's genetic makeup. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2024, about 129 million people in the U.S. have at least one major chronic disease, such as heart disease, cancer, or diabetes, as defined by the U.S. Department of Health and Human Services. An increasing proportion of people in America are dealing with multiple chronic conditions 42% have two or more, and 12% have at least five.

Country Insights

Increasing investments in research and developments, government programs promoting the use of mRNA-based medicines, and the rising number of clinical trials contribute to the growth of the U.S. mRNA therapeutics market. Rising advancements in mRNA technology can positively impact the market. Moreover, rising awareness about the benefits of mRNA in disease treatment fuels market growth.

Market News

• In July 2024, the U.S. government announced that it will pay the vaccine maker Moderna USD 176 million to develop a pandemic vaccine that could be used to treat bird flu in people as cases in dairy cows continue to mount across the country.
• In March 2024, Perlmutter Cancer Center Clinical Trial tested a personalized mRNA vaccine for treating Metastatic Melanoma that combines the immunotherapy drug pembrolizumab with V 940. V940 trains the immune system to attack proteins called neoantigens that are specific to a patient’s tumor and not found in normal tissue.

US mRNA Therapeutics Market Key Players

• GSK plc.
• BioNTech SE
• CureVac N.V.
• Sangamo Therapeutics, Inc.
• Translate Bio, Inc.
• Moderna, Inc.
• Argos Therapeutics Inc.
• Arcturus Therapeutics
• AstraZeneca plc.
• Pfizer Inc.
• CRISPR Therapeutics AG

Market Segmentation

By Type

• Therapeutic Vaccines
• Prophylactic Vaccines

By Application

• Oncology
• Rare Genetic Diseases
• Infectious Diseases
• Others

By End-use

• Research Organizations
• Hospitals and Clinics
• Others

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview@ https://www.precedenceresearch.com/checkout/3862

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344